Minerva raised up to $200 million in a private placement to fund a confirmatory Phase 3 trial of roluperidone, resubmission of its NDA, and preparation for a potential US commercial launch. The company co-developed seltorexant with Janssen Pharmaceutica NV for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder, with Janssen currently conducting Phase 3 trials.
Cyborg Score Rationale
The FDA confirmed that a new confirmatory clinical trial is required for roluperidone's NDA resubmission following a Complete Response Letter received in February 2024. While the company secured significant financing to advance its lead program, it remains pre-commercial with no approved products or generated revenue.
Top Insights
Completed a private placement generating $80 million upfront with up to $200 million additional available if warrant milestones are met (October 2025).
FDA confirmed new confirmatory Phase 3 trial required after Complete Response Letter for roluperidone in February 2024.
Company has not received any regulatory approvals and has not generated any revenue from product sales or licenses.
Minimal headcount with 8 employees as of February 2026.
Named Competitors
Antipsychotics (Various) — Established schizophrenia treatments
Seltorexant — Co-developed with Minerva for insomnia and depression
Levodopa and variants — Standard Parkinson's disease treatments
Recent Developments
(February 2026) Scheduled KOL event on roluperidone and negative symptoms in schizophrenia
(October 2025) Completed Series A private placement generating $80 million upfront
(May 2025) Appointed Dr. Inderjit Kaul to board of directors
Open the full interactive Minerva Neurosciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.